Subtopic Deep Dive

Thapsigargin Pharmacology
Research Guide

What is Thapsigargin Pharmacology?

Thapsigargin pharmacology examines the sesquiterpene lactone from Thapsia garganica as a SERCA inhibitor inducing ER stress and apoptosis in cancer cells, with focus on prodrug strategies like mipsagargin for targeted delivery.

Thapsigargin, isolated from Thapsia L., blocks sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pumps, elevating cytosolic calcium and triggering apoptosis (Andersen et al., 2015, 108 citations). Research advances prodrug forms for prostate cancer therapy and explores toxicity mitigation. Over 100 papers detail its Asteraceae-derived pharmacology.

Curated Papers

Key Challenges

Why It Matters

Thapsigargin's SERCA inhibition exploits calcium dysregulation in prostate cancer for focal prodrug delivery via mipsagargin, reaching Phase II trials (Andersen et al., 2015). Sesquiterpene lactones like costunolide and xanthatin show broad anti-cancer effects through NF-κB disruption and cell cycle arrest (Rasul et al., 2012; Zhang et al., 2012). These compounds advance Asteraceae-based therapies for malignancies including pancreatic and lung cancers (Laurella et al., 2022; Dhyani et al., 2022).

Key Research Challenges

Toxicity Mitigation

Thapsigargin causes non-specific SERCA inhibition leading to systemic toxicity, limiting clinical use (Andersen et al., 2015). Prodrug strategies like mipsagargin aim for tumor-selective activation but face delivery challenges. Balancing efficacy and safety remains critical.

Prodrug Delivery Optimization

Focal delivery requires protease-dependent activation in cancer tissues, with variable expression hindering uniformity (Andersen et al., 2015). Preclinical models show promise but human translation is slow. Engineering stability and specificity is key.

Combination Therapy Resistance

Cancer cells develop resistance to ER stress-induced apoptosis from thapsigargin-like lactones (Dhyani et al., 2022). NF-κB pathway activation counters effects in lung cancer models (Zhang et al., 2012). Synergy identification with chemotherapeutics is needed.

Essential Papers

Applications of Sesquiterpene Lactones: A Review of Some Potential Success Cases

Laila Moujir, Oliver Callies, Pedro M. C. Sousa et al. · 2020 · Applied Sciences · 140 citations

Sesquiterpene lactones, a vast range of terpenoids isolated from Asteraceae species, exhibit a broad spectrum of biological effects and several of them are already commercially available, such as a...

Thapsigargin—From Thapsia L. to Mipsagargin

Trine B. Andersen, Carmen López, Tom Manczak et al. · 2015 · Molecules · 108 citations

The sesquiterpene lactone thapsigargin is found in the plant Thapsia garganica L., and is one of the major constituents of the roots and fruits of this Mediterranean species. In 1978, the first pha...

Anti-Inflammatory and Immunoregulatory Action of Sesquiterpene Lactones

Ana Paço, Teresa Brás, Jacqueline Oliveira dos Santos et al. · 2022 · Molecules · 99 citations

Sesquiterpene lactones (SL), characterized by their high prevalence in the Asteraceae family, are one of the major groups of secondary metabolites found in plants. Researchers from distinct researc...

Sesquiterpene lactone! a promising antioxidant, anticancer and moderate antinociceptive agent from Artemisia macrocephala jacquem

Muhammad Harris Shoaib, Ismail Shah, Niaz Ali et al. · 2017 · BMC Complementary and Alternative Medicine · 83 citations

Sesquiterpenes lactones (STLs) are widely present in numerous genera of the family Asteraceae (compositae). They are described as the active constituents used in traditional medicine for the treatm...

Sesquiterpenoid lactones as potential anti-cancer agents: an update on molecular mechanisms and recent studies

Praveen Dhyani, Priyanka Sati, Eshita Sharma et al. · 2022 · Cancer Cell International · 62 citations

Xanthatin Induces Cell Cycle Arrest at G2/M Checkpoint and Apoptosis via Disrupting NF-κB Pathway in A549 Non-Small-Cell Lung Cancer Cells

Lei Zhang, Junshan Ruan, Yan Ling-geng et al. · 2012 · Molecules · 58 citations

Xanthatin, a natural sesquiterpene lactone, has significant antitumor activity against a variety of cancer cells, yet little is known about its anticancer mechanism. In this study, we demonstrated ...

Costunolide: A novel anti-cancer sesquiterpene lactone

Azhar Rasul, Saima Parveen, Tonghui Ma · 2012 · Bangladesh Journal of Pharmacology · 42 citations

Currently an ample interest is found among oncologists to explore anticancer compounds from herbs. Sesquiterpene lactones have accredited significant attention in pharmacological research. Costunol...

Reading Guide

Foundational Papers

Start with Andersen et al. (2015, 108 citations) for thapsigargin's pharmacology and prodrug history from Thapsia L.; follow with Zhang et al. (2012, 58 citations) and Rasul et al. (2012, 42 citations) for sesquiterpene lactone apoptosis mechanisms in cancer cells.

Recent Advances

Study Laurella et al. (2022, 35 citations) for pancreatic cancer applications and Dhyani et al. (2022, 62 citations) for updated molecular mechanisms of anti-cancer sesquiterpenoids.

Core Methods

Core techniques: SERCA pump assays, ER calcium flux measurement, MTT cytotoxicity, flow cytometry for apoptosis, xenograft models for prodrug testing, NF-κB pathway inhibition studies.

How PapersFlow Helps You Research Thapsigargin Pharmacology

Discover & Search

Research Agent uses searchPapers and exaSearch to find thapsigargin-focused sesquiterpene papers like 'Thapsigargin—From Thapsia L. to Mipsagargin' (Andersen et al., 2015), then citationGraph reveals 108 citing works on prodrugs, while findSimilarPapers uncovers related SERCA inhibitors from Asteraceae.

Analyze & Verify

Analysis Agent applies readPaperContent to extract SERCA inhibition mechanisms from Andersen et al. (2015), verifies apoptosis claims with verifyResponse (CoVe) against 10+ papers, and uses runPythonAnalysis for dose-response curve fitting from cytotoxicity data with GRADE scoring for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in prodrug clinical translation via gap detection on 50+ papers, flags NF-κB resistance contradictions (Zhang et al., 2012 vs. Rasul et al., 2012), then Writing Agent uses latexEditText, latexSyncCitations, and latexCompile to generate a review manuscript with exportMermaid diagrams of ER stress pathways.

Use Cases

"Extract IC50 values for thapsigargin in prostate cancer cell lines and plot dose-response."

Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib for IC50 curve fitting and GRADE verification) → matplotlib plot of EC50 comparisons across 5 papers.

"Write LaTeX section on thapsigargin prodrug mechanisms with citations."

Synthesis Agent → gap detection → Writing Agent → latexEditText (draft text) → latexSyncCitations (Andersen 2015 et al.) → latexCompile → PDF with ER stress pathway figure.

"Find GitHub repos analyzing sesquiterpene lactone cytotoxicity data."

Research Agent → searchPapers (xanthatin/costunolide) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → CSV export of apoptosis assay scripts from Zhang et al. (2012) implementations.

Automated Workflows

Deep Research workflow scans 50+ sesquiterpene papers for thapsigargin pharmacology, chaining searchPapers → citationGraph → structured report on SERCA mechanisms with GRADE scores. DeepScan applies 7-step analysis to Andersen et al. (2015) with CoVe checkpoints for prodrug claims. Theorizer generates hypotheses on Asteraceae lactone synergies from Dhyani et al. (2022).

Try Doxa for Thapsigargin Pharmacology Research

Frequently Asked Questions

What defines thapsigargin pharmacology?

Thapsigargin pharmacology studies its SERCA inhibition from Thapsia garganica roots, inducing ER stress apoptosis, with prodrugs like mipsagargin for cancer targeting (Andersen et al., 2015).

What are key methods in thapsigargin research?

Methods include cytotoxicity MTT assays, calcium imaging for SERCA block, and xenograft models for prodrug efficacy (Andersen et al., 2015; Zhang et al., 2012).

What are landmark papers?

Andersen et al. (2015, 108 citations) reviews thapsigargin to mipsagargin; Zhang et al. (2012, 58 citations) details NF-κB apoptosis in lung cancer.

What open problems exist?

Challenges include systemic toxicity reduction, uniform prodrug activation in tumors, and resistance via NF-κB in combination therapies (Dhyani et al., 2022; Andersen et al., 2015).